Contact us   |  

Kaposi sarcoma herpes virus-associated multicentric Castleman disease and HHV-8-associated multicentric Castleman disease (KSHV/HHV8 MCD)

Kaposi sarcoma herpes virus-associated multicentric Castleman disease and HHV-8-associated multicentric Castleman disease (KSHV/HHV8 MCD)

08/03/2022 15:00

Speakers: Mark Bower, David Boutboul

Target: Health professionals
Subnetworks: Lymphoid malignancies
Disease Groups: Castleman Disease

Prof Dr Mark Bower is a consultant medical oncologist at Chelsea & Westminster Hospital and Professor at Imperial College who specialises in the treatment of AIDS-related malignancies. He has developed one of the largest centres for the management of these tumours in Europe, receiving referrals from throughout the UK and has cared for over 3,000 patients with HIV-associated cancers. His clinical research covers the epidemiology, aetiology, pathogenesis and management of these tumours. He has a laboratory programme studying the immunopathology of these tumours in collaboration with a number of basic scientists. His laboratory research programme has been supported by over £3M in grant income and he has published >400 papers. He has delivered plenary lectures on HIV and cancer in five continents. He has written national (BHIVA), European (EACS) and global (WHO) clinical guidelines for the management of cancer in people living with HIV. He is a scientific advisor to UNAIDS.


Dr David Boutboul graduated from the Université Paris Descartes in 2008 after a residency in Clinical Immunology. He studied the genetic basis of CVID-associated lymphoproliferative disorders during his PhD at Université Paris Diderot and joined the team of Dr S. Latour/Pr A. Fischer in 2015 at Institute Imagine for a post-doctoral fellowship studying genetics of EBV susceptibility and IKZF1 germline mutations in children with primary immune deficiencies. He's now Associate Professor in the Clinical Immunology Unit at Hôpital Saint Louis, Paris. He recently developed a research activity in the U976 HIPI unit, leading a team working on the pathophysiology of Castleman disease (HHV8-related Castleman disease and Unicentric Castleman disease).